67 related articles for article (PubMed ID: 22285275)
21. Long-term safety and efficacy of zonisamide in patients with refractory partial-onset epilepsy.
Wroe SJ; Yeates AB; Marshall A
Acta Neurol Scand; 2008 Aug; 118(2):87-93. PubMed ID: 18547272
[TBL] [Abstract][Full Text] [Related]
22. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study.
Novick D; Haro JM; Bertsch J; Haddad PM
J Clin Psychopharmacol; 2010 Oct; 30(5):531-40. PubMed ID: 20814320
[TBL] [Abstract][Full Text] [Related]
23. Case series: spectrum of neuroleptic-induced movement disorders and extrapyramidal side effects in childhood-onset schizophrenia.
Kumra S; Jacobsen LK; Lenane M; Smith A; Lee P; Malanga CJ; Karp BI; Hamburger S; Rapoport JL
J Am Acad Child Adolesc Psychiatry; 1998 Feb; 37(2):221-7. PubMed ID: 9473920
[TBL] [Abstract][Full Text] [Related]
24. Adjunctive zonisamide for treatment refractory anxiety.
Kinrys G; Vasconcelos e Sa D; Nery F
Int J Clin Pract; 2007 Jun; 61(6):1050-3. PubMed ID: 17504366
[TBL] [Abstract][Full Text] [Related]
25. Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: an open-label study.
Miyaoka T; Furuya M; Yasuda H; Hayashida M; Nishida A; Inagaki T; Horiguchi J
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):761-4. PubMed ID: 18201810
[TBL] [Abstract][Full Text] [Related]
26. Evidence for association of the GLI2 gene with tardive dyskinesia in patients with chronic schizophrenia.
Greenbaum L; Alkelai A; Rigbi A; Kohn Y; Lerer B
Mov Disord; 2010 Dec; 25(16):2809-17. PubMed ID: 20939080
[TBL] [Abstract][Full Text] [Related]
27. A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive Dyskinesia.
Marder SR; Singer C; Lindenmayer JP; Tanner CM; Comella CL; Verghese C; Jimenez R; Liang GS; Burke J; OʼBrien CF
J Clin Psychopharmacol; 2019; 39(6):620-627. PubMed ID: 31688452
[TBL] [Abstract][Full Text] [Related]
28. Zonisamide in the treatment of binge-eating disorder: an open-label, prospective trial.
McElroy SL; Kotwal R; Hudson JI; Nelson EB; Keck PE
J Clin Psychiatry; 2004 Jan; 65(1):50-6. PubMed ID: 14744168
[TBL] [Abstract][Full Text] [Related]
29. Zonisamide produces weight loss in psychotropic drug-treated psychiatric outpatients.
Lim J; Ko YH; Joe SH; Han C; Lee MS; Yang J
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Dec; 35(8):1918-21. PubMed ID: 21803114
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological treatment of tardive dyskinesia: recent developments.
Caroff SN; Campbell EC; Carroll B
Expert Rev Neurother; 2017 Sep; 17(9):871-881. PubMed ID: 28727483
[TBL] [Abstract][Full Text] [Related]
31. Tardive dyskinesia (syndrome): Current concept and modern approaches to its management.
Lerner PP; Miodownik C; Lerner V
Psychiatry Clin Neurosci; 2015 Jun; 69(6):321-34. PubMed ID: 25556809
[TBL] [Abstract][Full Text] [Related]
32. The Use of Zonisamide for the Treatment of Psychiatric Disorders: A Systematic Review.
Buoli M; Grassi S; Ciappolino V; Serati M; Altamura AC
Clin Neuropharmacol; 2017; 40(2):85-92. PubMed ID: 28195838
[TBL] [Abstract][Full Text] [Related]
33. Zonisamide for bipolar depression.
Wilson MS; Findling RL
Expert Opin Pharmacother; 2007 Jan; 8(1):111-3. PubMed ID: 17163811
[TBL] [Abstract][Full Text] [Related]
34. Open label trial of the tolerability and efficacy of zonisamide in the treatment of alcohol dependence.
Knapp CM; Sarid-Segal O; Richardson MA; Colaneri LS; Afshar M; Devine E; Streeter CC; Piechniczek-Buczek J; Ciraulo DA
Am J Drug Alcohol Abuse; 2010 Mar; 36(2):102-5. PubMed ID: 20337506
[TBL] [Abstract][Full Text] [Related]
35. A review of the use of zonisamide in Parkinson's disease.
Bermejo PE; Anciones B
Ther Adv Neurol Disord; 2009 Sep; 2(5):313-7. PubMed ID: 21180621
[TBL] [Abstract][Full Text] [Related]
36. Treatment of phenothiazine-induced dyskinesia.
Goldman D
Psychopharmacology (Berl); 1976 Jun; 47(3):271-2. PubMed ID: 9653
[TBL] [Abstract][Full Text] [Related]
37. Zonisamide in Parkinson's disease: profile report.
Yang LP; Perry CM
Drugs Aging; 2010 Jan; 27(1):73-5. PubMed ID: 20030434
[No Abstract] [Full Text] [Related]
38. Levodopa-Induced Dyskinesias in Parkinson's Disease: An Overview on Pathophysiology, Clinical Manifestations, Therapy Management Strategies and Future Directions.
di Biase L; Pecoraro PM; Carbone SP; Caminiti ML; Di Lazzaro V
J Clin Med; 2023 Jun; 12(13):. PubMed ID: 37445461
[TBL] [Abstract][Full Text] [Related]
39. Antiseizure Drugs and Movement Disorders.
Sáenz-Farret M; Tijssen MAJ; Eliashiv D; Fisher RS; Sethi K; Fasano A
CNS Drugs; 2022 Aug; 36(8):859-876. PubMed ID: 35861924
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms and Pharmacotherapy for Ethanol-Responsive Movement Disorders.
Wu J; Tang H; Chen S; Cao L
Front Neurol; 2020; 11():892. PubMed ID: 32982923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
